Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: lack (201), deficiency (110), absence (193), shortage (91)

Atezolizumab-Bevacizumab-Carboplatin(AUC6)-Paclitaxel

Description: Chemotherapy Protocol LUNG CANCER ATEZOLIZUMAB-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACLITAXEL Regimen  Lung-Atezolizumab-Bevacizumab-Carboplatin (AUC6)-Paclitaxel Indication  The treatment of adult pati
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab-Bevacizumab-CarboplatinAUC6-Paclitaxel.pdf

Atezolizumab-Bevacizumab

Description: Chemotherapy Protocol Hepatocellular Cancer ATEZOLIZUMAB-BEVACIZUMAB Regimen  HCC-Atezolizumab-Bevacizumab Indication  Atezolizumab in combination with bevacizumab for the first-lin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Atezolizumab-Bevacizumab.pdf

Atezolizumab-Paclitaxel Albumin Bound

Description: Chemotherapy Protocol BREAST CANCER Atezolizumab-Paclitaxel Albumin Bound Regimen • Breast – Atezolizumab-Paclitaxel Albumin Bound Indication • Atezolizumab in combination with paclitaxel album
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Atezolizumab-Paclitaxel-Albumin-Bound.pdf

Material risks

Description: The General Medical Council makes it clear that a well established risk of serious adverse outcome is significant for the purpose
Url: /HealthProfessionals/Clinical-law-updates/Material-risks.aspx

Dabrafenib Trametinib Ver1

Description: Chemotherapy Protocol SKIN CANCER DABRAFENIB-TRAMETINIB Regimen  Skin – Dabrafenib-Trametinib Indication  The combination of dabrafenib and tra
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinDabrafenibTrametinibVer1.pdf

AmB-LISOCEL-Cyclophosphamide (300)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AmB – LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) Ambulat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LISOCEL-Cyclophosphamide-300-Fludarabine-30.pdf

Lisocel – Cyclophosphamide (300) – Fludarabine (30) Ver1

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) This regimen
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lisocel-–-Cyclophosphamide-300-–-Fludarabine-30.pdf

AmB-Axicabtagene ciloleucel-Cyclophosphamide (500)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Large B-cell Lymphoma (LBL) AmB- AXICEL – CYCLOPHOSPHAMIDE (500
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Axicabtagene-ciloleucel-Cyclophosphamide-500-Fludarabine-30.pdf

AmB - Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Mantle Cell lymphoma (MCL) AmB – BREXUCEL – CYCLOPHOSPHAMIDE (5
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Brexucel-Cyclophosphamide-500-Fludarabine-30-Ver-1.pdf

Tisacel-Cytarabine (500)-Etoposide (150)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL – CYTARABINE (500) – ETOPOSIDE (150) Regimen This
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cytarabine-500-Etoposide-150.pdf

51 to 60 of 72

Previous … 4 5 6 7 8 Next